



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 31/702, 31/715, A61P 1/04		A1	(11) International Publication Number: WO 00/56343 (43) International Publication Date: 28 September 2000 (28.09.00)		
(21) International Application Number:	PCT/SE00/00514	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SI, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).			
(22) International Filing Date:	16 March 2000 (16.03.00)				
(30) Priority Data: 9901007-6	19 March 1999 (19.03.99)	SE			
(71)(72) Applicant and Inventor: BORÉN, Thomas [SE/SE]; Torevägen 68, S-906 28 Umeå (SE).					
(72) Inventors; and					
(75) Inventors/Applicants (for US only): HAMMARSTRÖM, Lennart [SE/SE]; Blomstergård 79, S-141 44 Huddinge (SE); KARLSSON, Karl-Anders [SE/SE]; Nilssonsberg 37, S-411 43 Göteborg (SE); TENEBERG, Susann [SE/SE]; Andviken, Pl 1639, S-430 63 Hindås (SE).					
(74) Agent: BERGENSTRÄHLE & LINDVALL AB; P.O. Box 17704, S-118 93 Stockholm (SE).					
(64) Title: USE OF FUOSYLATED SIALYLATED N-ACETYL LACTOSAMINE CARBOHYDRATE STRUCTURES FOR INHIBITION OF BACTERIAL ADHERENCE		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(57) Abstract					
A fucosylated sialylated N-acetyl lactosamine structure such as a sialyl-Lewis antigen carbohydrate structure, for example sialyl-Lewis x and in particular dimeric or repetitive sialyl-Lewis x can be used for the preparation of a pharmaceutical composition for the treatment or prophylaxis in humans of conditions involving infection by <i>Helicobacter pylori</i> and related pathogens of the human gastrointestinal mucosa. Further, said conditions can be treated through the administration of a fucosylated sialylated lactosamine structure, such as a sialyl-Lewis antigen carbohydrate structure or corresponding antibodies to patients in need thereof.					